Phase 1 First in Human Dose-Escalation Study of ZN-d5 as a Single Agent in Subjects With Non-Hodgkin Lymphoma or Acute Myeloid Leukemia
Latest Information Update: 26 Sep 2024
At a glance
- Drugs ZN d5 (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; First in man
- Sponsors K-Group Alpha
- 12 Sep 2024 Status changed from recruiting to completed.
- 05 Apr 2023 Primary and secondary outcome measures amended. Inclusion and exclusion criteria amended.
- 05 Apr 2023 Planned number of patients changed from 85 to 115.